share_log

Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M

Valneva Raised 2024 Product Sales Guidance To €160M-€180M (Prior €150M-€180M); Sees Total Revenues Of €170M-€190M

Valneva将2024年的产品销售预期提高至1.6亿至1.8亿欧元(之前为1.5亿至1.8亿欧元);预计总收入为1.7亿欧元至1.9亿欧元
Benzinga ·  03/20 02:32

Updated FY 2024 guidance

更新的 2024 财年指南

  • Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an improved outlook regarding the IXIARO supply constraints that were anticipated in February 2024.
  • As such, 2024 total revenues are now expected to reach between €170 million and €190 million compared to €153.7 million in 2023, driven by continued sales growth of the Company's proprietary travel vaccines and the launch-year sales of IXCHIQ.
  • Sales are expected to grow this year despite an estimated 20-30% reduction in third-party sales as a result of anticipated supply constraints.
  • In 2024, the Company anticipates lower R&D expenses than previously communicated, narrowing guidance to €60 million to €75 million, based on additional visibility for its chikungunya- and Zika- related expenses. Additionally, Valneva expects non-dilutive contributions from institutions for R&D costs in connection with its ongoing chikungunya activities and the product tech transfers to Valneva's brand-new state-of the art facility ("Almeida") in Scotland.
  • Other income is now expected between €100 million and €110 million in 2024, reflecting €95 million in proceeds from the PRV sale in early 2024.
  • Valneva anticipates a significantly lower cash burn this year than in 2023 and expects its commercial business to be cash-flow positive and contribute significantly to funding the Company's R&D from 2025.
  • Valneva将其2024年的产品销售4预期上调至1.6亿欧元至1.8亿欧元之间,这是由于预计在2024年2月出现的IXIARO供应限制的前景有所改善。
  • 因此,受公司专有旅行疫苗销售持续增长和IXCHIQ上市年销售额的推动,2024年的总收入预计将达到1.7亿欧元至1.9亿欧元,而2023年为1.537亿欧元。
  • 尽管由于预期的供应限制,第三方销售额预计将减少20-30%,但今年的销售额仍将增长。
  • 基于其基孔肯雅热和寨卡相关支出的可见度提高,该公司预计2024年的研发费用将低于先前公布的研发费用,将预期范围缩小至6000万欧元至7,500万欧元。此外,Valneva预计,与其正在进行的基孔肯雅热活动以及向Valneva在苏格兰的全新最先进设施(“Almeida”)转让产品技术相关的研发费用将获得机构非稀释性捐款。
  • 现在,预计2024年的其他收入将在1亿欧元至1.1亿欧元之间,反映了2024年初出售PRV的9500万欧元收益。
  • Valneva预计,今年的现金消耗将比2023年低得多,并预计从2025年起,其商业业务将实现正现金流,并为公司的研发资金做出重大贡献。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发